All In Biotech

Drug Trial Radar · NCT00866619

Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa

Efficacy of GSK Biologicals' Candidate Malaria Vaccine (257049) Against Malaria Disease Caused by P. Falciparum Infection in Infants and Children in Africa

Last checked: Nov 19, 2026Latest source record: Oct 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 15,459 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

15,459

Actual

Start

Mar 27, 2009

Primary completion

Mar 1, 2011

Study completion Jan 31, 2014

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
The PATH Malaria Vaccine Initiative (MVI)
First posted
Mar 20, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 6 weeks, up to 17 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this observer-blind study is to gather key efficacy, safety, and immunogenicity information on GSK's candidate malaria vaccine in infants and children.

Conditions

  • Malaria

Interventions

  • Malaria Vaccine 257049Biological

    administered intramuscularly into the left deltoid.

  • Meningococcal C Conjugate VaccineBiological

    administered intramuscularly into the left deltoid.

  • Cell-culture rabies vaccineBiological

    administered intramuscularly into the left deltoid.

  • TritanrixHepB/HibBiological

    administered intramuscularly into the left deltoid.

  • Polio Sabin Oral Polio Vaccine (GSK)Biological

    administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of First or Only Clinical Episode of Plasmodium Falciparum (P. Falciparum) Malaria Infection (CPFMI), or Clinical Malaria Episode of Primary Case Definition (CPFMI-PCD)Time frame: From Month 2.5 to Month 14
  2. Rate of First or Only Clinical Episode of P. Falciparum Malaria Infection (CPFMI), or Clinical Malaria Episode of Primary Case Definition (CPFMI-PCD)Time frame: From Month 2.5 to Month 14

Locations

10 sites in 7 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Ouagadougou, Burkina Faso

  • GSK Investigational Site

    Lambaréné, Gabon

  • GSK Investigational Site

    Kintampo, Ghana

  • GSK Investigational Site

    Kumasi, Ghana

  • GSK Investigational Site

    Kilifi, Kenya

  • GSK Investigational Site

    Kisumu, Kenya

  • GSK Investigational Site

    Lilongwe, Malawi

  • GSK Investigational Site

    Maputo, Mozambique

  • GSK Investigational Site

    Dar es Salaam, Tanzania

  • GSK Investigational Site

    Tanga, Tanzania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.